Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial.
INTRODUCTION: We previously reported evidence that the T allele of the dopamine type-2 receptor (DRD2) rs1800497 polymorphism is associated with improved response to nicotine replacement therapy (NRT) relative to placebo and that this association may only be present in females. However, evidence of...
Main Authors: | Munafò, MR, Johnstone, E, Murphy, M, Aveyard, P |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2009
|
Similar Items
-
Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial
by: Munafo, M, et al.
Published: (2009) -
A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation.
by: Welton, N, et al.
Published: (2008) -
Smoking cessation, weight gain, and DRD4 -521 genotype
by: Munafò, MR, et al.
Published: (2006) -
Distribution of Dopamine Receptor 2 DRD2 rs1800497 Polymorphisms in Professional Football Players
by: Beste Tacal Aslan, et al.
Published: (2021-08-01) -
Association of expression of DRD2 rs1800497 polymorphism with migraine risk in Han Chinese individuals
by: Deng Y, et al.
Published: (2018-04-01)